Moderna Stock (MRNA)

XNGS Sideways Alert Compare

Health Care · Fundamental analysis and chart analysis

· How we analyze

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Moderna is a US biotech company built on mRNA technology. It became known for its Covid-19 vaccine. It also develops vaccines against RSV and flu as well as cancer and other therapies based on mRNA. As of Oct 11, 2026

Fact sheet (from the annual report) Biotechnology and vaccines · Cambridge, USA

The company develops mRNA-based vaccines and therapies for infectious diseases, oncology and rare diseases. It markets the vaccines Spikevax and mNEXSPIKE against COVID and mRESVIA against the respiratory virus RSV. Revenue in 2025 came largely from the COVID vaccines. According to the company, mNEXSPIKE, launched in 2025, was ahead of its other products in the US retail channel as of the report. Its research comprises programs in infectious diseases, oncology and rare diseases, partly together with Merck.

Automatically summarized from SEC annual report (10-K, filed Feb 20, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −2.2%
  • 7 days −12.7%
  • 30 days −20.7%
  • 1 year +772.1%
Day range (last trading day)
−1.8%Price at 19% of the range+7.7%
52-week range
−88.6%Price at 67% of the range+44.0%
Distance from the all-time high
−60.8%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Detected chart patterns

  • Double bottom on the daily chart, detected on Nov 4, 2026

Chart patterns with zone, stop and targets

Free account

13 patterns with a zone · 11 Warning patterns · detected in 23 symbols

You see the zone, stop, two targets and the pattern lines in the chart with a free account.

  • Ascending triangle
  • Flag
  • Falling wedge
  • Inverse head and shoulders
  • Cup with handle
  • Range breakout
  • Double bottom
  • Pullback in trend
  • 52-week-high breakout
  • Gap with volume
  • Double top
  • Head and shoulders
  • Descending triangle

Create a free account

Free with an account until Jan 31, 2027: all Premium features, no subscription and no card. Sign up free

Earlier patterns · Past performance, not a forecast

Premium The list of earlier chart patterns of this asset with their outcome is available with a free account.

Chart analysis: trend by timeframe

  1. 1W weekly candles up
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • higher highs and higher lows

    Price above the EMA 20 · above the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · below the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles mixed
    • Close above the SMA 200
    • EMA 20 below the EMA 50
    • higher highs and higher lows

    Price below the EMA 20 · below the EMA 50

    Candle from Nov 20, 2026, 19:30

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran stronger than the S&P 500 and stronger than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
stronger
vs. S&P 500 · 6 months
stronger
vs. sector · 3 months
stronger
  • Trend above SMA 200 Price above the 200-day line – above it the long-term trend counts as up; ADX above 25 – a pronounced trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line below its signal line (gap below 0).
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility high Typical daily range (ATR 14) above 4% of the price – high.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran stronger.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

For November, 7 of 10 years are available – too few to say anything (at least 8 needed).

Months mostly higher
5 of 10
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 5 of 8 years
  • February: higher in 3 of 8 years
  • March: higher in 4 of 8 years
  • April: higher in 5 of 8 years
  • May: higher in 5 of 8 years
  • June: higher in 4 of 8 years
  • July: higher in 5 of 8 years
  • August: higher in 3 of 8 years
  • September: higher in 5 of 8 years
  • October: higher in 4 of 8 years
  • November (current month): too little data (7 years)
  • December: too little data (7 years)
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January5 of 8
February3 of 8
March4 of 8
April5 of 8
May5 of 8
June4 of 8
July5 of 8
August3 of 8
September5 of 8
October4 of 8
November ●too little data (7 years)
Decembertoo little data (7 years)

Through October 2026 (last completed month) · from our daily candles

Opportunity at a glance Moderna

Pattern on the chart: Double bottom on the daily chart, detected on Nov 4, 2026 – Entry area, stop and targets are calculated. You see these and all other figures on the card with a free account.

Create a free account

What does this mean? The card sums up patterns, potential, risk and supports on the 4H, daily and weekly chart.

Potential to target 1hidden 4-hour or daily chart
Risk to stop
hidden
Reward/risk
hidden

Remaining potential: moved since detection and still open to target 1 – each in % with timeframe.

Trend 4H mixed 1D mixed 1W up

In favour 0 · Against 2 Points without chart-pattern detail – you see every point with figure and date with a free account

Fundamental analysis

Moderna · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 20, 2026.

For you first Dividend

The company pays no dividend.

For you first Valuation

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
1 of 6
criteria with data met
Revenue per year (5 y)
+19.3%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
2 of 8
criteria with data met
Net margin
−145.2%
Return on equity
−32.6%

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
up
daily candles
mixed
4-hour candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 2 of 8 met

  • met: Gross margin above 40% 55.3%
  • not met: Operating margin above 15% −158.1%
  • not met: Net margin above 10% −145.2%
  • not met: Return on equity above 15% −32.6%
  • not met: Free cash flow margin above 10% −106.2%
  • not met: Profit in each of the last 5 fiscal years 2 of 5
  • not met: Free cash flow positive in each of the last 3 fiscal years 0 of 3
  • met: Equity ratio above 30% 70.1%
Gross margin

55.3% Fiscal year 2025

Rank 62 of 100: higher than 62% of 370 peers (All). medium.

Rank 36 of 100: higher than 36% of 49 peers (Sector). medium.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

−158.1% Fiscal year 2025

Rank 4 of 100: higher than 4% of 470 peers (All). weak.

Rank 3 of 100: higher than 3% of 54 peers (Sector). weak.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

−145.2% Fiscal year 2025

Rank 4 of 100: higher than 4% of 584 peers (All). weak.

Rank 4 of 100: higher than 4% of 63 peers (Sector). weak.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

−32.6% Fiscal year 2025

Rank 5 of 100: higher than 5% of 544 peers (All). weak.

Rank 5 of 100: higher than 5% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

−22.9% Fiscal year 2025 (total assets at year end)

Rank 3 of 100: higher than 3% of 594 peers (All). weak.

Rank 4 of 100: higher than 4% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

70.1% Fiscal year 2025

Rank 90 of 100: higher than 90% of 595 peers (All). strong.

Rank 83 of 100: higher than 83% of 63 peers (Sector). strong.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

−106.2% Fiscal year 2025

Rank 5 of 100: higher than 5% of 465 peers (All). weak.

Rank 4 of 100: higher than 4% of 61 peers (Sector). weak.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

−2.1B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 1 of 6 met · 1 without data

  • not met: Over 3 years, revenue grew by more than 5% per year −53.4%
  • met: Over 5 years, revenue grew by more than 5% per year +19.3%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • not met: Over 3 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Over 5 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 2 of 5
  • not met: Revenue rose in the last fiscal year −39.9%
Revenue growth 3 years

−53.4% per year

Rank 0 of 100: higher than 0% of 578 peers (All). weak.

Rank 1 of 100: higher than 1% of 62 peers (Sector). weak.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+19.3% per year

Rank 81 of 100: higher than 81% of 549 peers (All). strong.

Rank 94 of 100: higher than 94% of 60 peers (Sector). strong.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 4 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 2 of 9
  • met: Long-term debt no higher than equity 0.07
  • met: Current assets cover current liabilities 3.29
  • met: Positive equity 8.7B USD
  • met: In 5 years, share count up by at most 5% +2.1%
  • not met: Free cash flow positive in the last fiscal year −2.1B USD
Piotroski F-Score

2 of 9 Fiscal year 2025

Rank 1 of 100: higher than 1% of 310 peers (All). weak.

Rank 1 of 100: higher than 1% of 47 peers (Sector). weak.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.07 at fiscal year end

Rank 91 of 100: lower than 91% of 486 peers (All). strong.

Rank 89 of 100: lower than 89% of 50 peers (Sector). strong.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

3.29 at fiscal year end

Rank 88 of 100: higher than 88% of 513 peers (All). strong.

Rank 88 of 100: higher than 88% of 63 peers (Sector). strong.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

+2.1% in 5 years

Rank 33 of 100: lower than 33% of 507 peers (All). medium.

Rank 19 of 100: lower than 19% of 59 peers (Sector). weak.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • not met: Profit in the last fiscal year (positive return on assets)
  • not met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • not met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+19.3% per year), at least as fast as the sector median.
  • Light red: Loss in the last fiscal year.
  • Light green: Debt not higher than usual in the sector.
  • Light red: Profit in 2 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 108.4M USD · Net income −216.2M USD · Net margin −199.5%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 205.8M USD · Net income −255.9M USD · Net margin −124.3%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 135.1M USD · Net income −384.7M USD · Net margin −284.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 60.2M USD · Net income −514.0M USD · Net margin −853.7%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 803.4M USD · Net income −747.1M USD · Net margin −93.0%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 18.5B USD · Net income 12.2B USD · Net margin 66.1%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 19.3B USD · Net income 8.4B USD · Net margin 43.4%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 6.8B USD · Net income −4.7B USD · Net margin −68.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 3.2B USD · Net income −3.6B USD · Net margin −110.0%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 1.9B USD · Net income −2.8B USD · Net margin −145.2%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 1.9B USD · Net income −2.8B USD · Net margin −145.2%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +29.2% vs. the same quarter a year earlier; grown for 3 quarters in a row.

Revenue 12 months vs. prior 12
+13.1%
12 months: 2.5B USD · Fiscal year 2025: −39.9%
Net margin 12 months
–
Fiscal year 2025: no value
Free cash flow margin 12 months
−78.0%
Fiscal year 2025: no value
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 1.9B USD + year to date to Sep 30, 2026 1.8B USD − same period a year earlier to Sep 30, 2025 1.3B USD = 2.5B USD
  • Net income: fiscal year to Dec 31, 2025 −2.8B USD + year to date to Sep 30, 2026 −2.0B USD − same period a year earlier to Sep 30, 2025 −2.0B USD = −2.8B USD
  • Operating cash flow: fiscal year to Dec 31, 2025 −1.9B USD + year to date to Sep 30, 2026 −2.7B USD − same period a year earlier to Sep 30, 2025 −2.8B USD = −1.8B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 192.0M USD + year to date to Sep 30, 2026 146.0M USD − same period a year earlier to Sep 30, 2025 153.0M USD = 185.0M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 261.3B+29.2%162.0M12.3%
Apr–Jun 26145.0M+2.1%−782.0M–
Jan–Mar 26389.0M+260.2%−1.3B–
Oct–Dec 25*678.0M−29.8%−826.0M–
Jul–Sep 251.0B−45.4%−200.0M−19.7%
Apr–Jun 25142.0M−41.1%−825.0M–
Jan–Mar 25108.0M−35.3%−971.0M–
Oct–Dec 24*966.0M−65.6%−1.1B–

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 6, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

There was no profit in fiscal year 2025; operating income does not cover interest.

Cash flow ÷ profit
–
no profit in fiscal year 2025
Interest coverage
negative
operating income negative · interest paid per cash flow statement · 3 years: negative
Tax rate
–
no profit before tax
More depth

Calculation for fiscal year 2025

  • Operating cash flow −1.9B USD ÷ Net income −2.8B USD = no ratio (no profit)
  • Operating income −3.1B USD ÷ interest paid per cash flow statement 10.0M USD = negative
  • Taxes 54.0M USD ÷ profit before tax −2.8B USD = no rate (no profit before tax)
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
2025–negative–
2024–negative–
2023–negative–
20220.60xover 100x12.7%
20211.12xover 100x8.2%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years 8 loss years; 5 years with lower revenue across 9 years with a prior-year figure.

Loss years
8 of 10
net income below zero
Years with lower revenue
5 of 9
revenue below the prior year
Net margin range
265.5 percentage points
from −199.5% to 66.1%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025−39.9%−145.2%
2024−52.7%−110.0%
2023−64.4%−68.8%
2022+4.3%43.4%
2021+2,199.1%66.1%
2020+1,234.3%−93.0%
2019−55.4%–
2018−34.4%–
2017+89.9%−124.3%
2016–−199.5%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Since when has today’s status held?

Check status by fiscal year

Quality: 2 of 8 criteria in every annual report since 2024; Financial strength in fiscal year 2025: 4 of 6 (prior year 2 of 5).

  • Quality 2 of 8 since FY 2024 · before that 1 of 8
  • Growth 1 of 6 since FY 2024 · before that 2 of 5
  • Dividend 0 of 1 in every annual report since 2021
  • Financial strength 4 of 6 since FY 2025 · before that 2 of 5
More depth
Criteria met by fiscal year (met/with data)
Check20212022202320242025
Quality6/87/81/82/82/8
Growth3/43/42/51/61/6
Dividend0/10/10/10/10/1
Financial strength3/33/42/42/54/6

Fiscal year 2025 with today’s status of the checks without price data (for accounts, the badges above also count P/E/PEG and dividend yield).

Earlier years as of the filing date of their annual report: FY 2024 on Feb 21, 2025, FY 2023 on Feb 23, 2024, FY 2022 on Feb 24, 2023, FY 2021 on Feb 25, 2022.

Recalculated only with SEC filings up to the respective filing date – later corrections are left out. Without price-based criteria (P/E, dividend yield); criteria without data do not count.

As of annual reports 2021–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 55.3 USD gross profit remained.

Operating loss: −158.1% of revenue

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue1.9B USD100.0%
Gross profit1.1B USD55.3%
Cost of revenue868.0M USD44.7%
Operating expenses4.2B USD213.5%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from −95.0% to −158.1%.

Gross marginOperating marginNet margin Margins above ±200% hidden (revenue very small relative to the result).
  1. Fiscal year 2016: Gross margin not available · Operating margin not available · Net margin −199.5%
  2. Fiscal year 2017: Gross margin not available · Operating margin −130.9% · Net margin −124.3%
  3. Fiscal year 2018: Gross margin not available · Operating margin not available · Net margin not available
  4. Fiscal year 2019: Gross margin not available · Operating margin not available · Net margin not available
  5. Fiscal year 2020: Gross margin not available · Operating margin −95.0% · Net margin −93.0%
  6. Fiscal year 2021: Gross margin 85.8% · Operating margin 72.0% · Net margin 66.1%
  7. Fiscal year 2022: Gross margin 71.9% · Operating margin 48.9% · Net margin 43.4%
  8. Fiscal year 2023: Gross margin 31.5% · Operating margin −61.9% · Net margin −68.8%
  9. Fiscal year 2024: Gross margin 54.8% · Operating margin −121.9% · Net margin −110.0%
  10. Fiscal year 2025: Gross margin 55.3% · Operating margin −158.1% · Net margin −145.2%

Returns

Return on equity fell in 5 years from −29.2% to −32.6%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity not available · Return on assets not available
  2. Fiscal year 2017: Return on equity not available · Return on assets −23.6%
  3. Fiscal year 2018: Return on equity −25.1% · Return on assets −19.6%
  4. Fiscal year 2019: Return on equity −43.8% · Return on assets −32.3%
  5. Fiscal year 2020: Return on equity −29.2% · Return on assets −10.2%
  6. Fiscal year 2021: Return on equity 86.3% · Return on assets 49.5%
  7. Fiscal year 2022: Return on equity 43.7% · Return on assets 32.3%
  8. Fiscal year 2023: Return on equity −34.0% · Return on assets −25.6%
  9. Fiscal year 2024: Return on equity −32.7% · Return on assets −25.2%
  10. Fiscal year 2025: Return on equity −32.6% · Return on assets −22.9%

Equity and long-term debt

The equity ratio rose in 5 years from 34.9% to 70.1%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity −334.8M USD · Long-term debt not available
  2. Fiscal year 2017: Equity −551.4M USD · Long-term debt not available
  3. Fiscal year 2018: Equity 1.5B USD · Long-term debt not available
  4. Fiscal year 2019: Equity 1.2B USD · Long-term debt not available
  5. Fiscal year 2020: Equity 2.6B USD · Long-term debt not available
  6. Fiscal year 2021: Equity 14.1B USD · Long-term debt not available
  7. Fiscal year 2022: Equity 19.1B USD · Long-term debt not available
  8. Fiscal year 2023: Equity 13.9B USD · Long-term debt not available
  9. Fiscal year 2024: Equity 10.9B USD · Long-term debt 0.0 USD
  10. Fiscal year 2025: Equity 8.7B USD · Long-term debt 590.0M USD

Liquidity (current ratio)

The current ratio rose in 5 years from 1.43 to 3.29.

Current ratio
  1. Fiscal year 2016: Current ratio not available
  2. Fiscal year 2017: Current ratio 4.09
  3. Fiscal year 2018: Current ratio 7.02
  4. Fiscal year 2019: Current ratio 7.89
  5. Fiscal year 2020: Current ratio 1.43
  6. Fiscal year 2021: Current ratio 1.76
  7. Fiscal year 2022: Current ratio 2.73
  8. Fiscal year 2023: Current ratio 3.42
  9. Fiscal year 2024: Current ratio 3.67
  10. Fiscal year 2025: Current ratio 3.29

Cash flow

Free cash flow fell in 5 years from 2.0B USD to −2.1B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 66.7M USD · Capital expenditure 33.1M USD · Free cash flow 33.6M USD
  2. Fiscal year 2017: Operating cash flow −331.5M USD · Capital expenditure 58.4M USD · Free cash flow −389.9M USD
  3. Fiscal year 2018: Operating cash flow −330.9M USD · Capital expenditure 105.8M USD · Free cash flow −436.6M USD
  4. Fiscal year 2019: Operating cash flow −459.0M USD · Capital expenditure 31.6M USD · Free cash flow −490.5M USD
  5. Fiscal year 2020: Operating cash flow 2.0B USD · Capital expenditure 67.4M USD · Free cash flow 2.0B USD
  6. Fiscal year 2021: Operating cash flow 13.6B USD · Capital expenditure 284.0M USD · Free cash flow 13.3B USD
  7. Fiscal year 2022: Operating cash flow 5.0B USD · Capital expenditure 400.0M USD · Free cash flow 4.6B USD
  8. Fiscal year 2023: Operating cash flow −3.1B USD · Capital expenditure 707.0M USD · Free cash flow −3.8B USD
  9. Fiscal year 2024: Operating cash flow −3.0B USD · Capital expenditure 1.1B USD · Free cash flow −4.1B USD
  10. Fiscal year 2025: Operating cash flow −1.9B USD · Capital expenditure 192.0M USD · Free cash flow −2.1B USD

Share count

The share count rose in 5 years by 2.1% – more new shares were issued than repurchased (dilution).

Diluted share count
  1. Fiscal year 2016: Diluted share count not available
  2. Fiscal year 2017: Diluted share count not available
  3. Fiscal year 2018: Diluted share count not available
  4. Fiscal year 2019: Diluted share count 331.0M
  5. Fiscal year 2020: Diluted share count 381.0M
  6. Fiscal year 2021: Diluted share count 431.0M
  7. Fiscal year 2022: Diluted share count 416.0M
  8. Fiscal year 2023: Diluted share count 382.0M
  9. Fiscal year 2024: Diluted share count 384.0M
  10. Fiscal year 2025: Diluted share count 389.0M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

No annual figures for this stock: Dividend per share, Payout ratio (earnings), Payout ratio (free cash flow).

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company pays no dividend.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none pays no dividend
To shareholders (5 years)
5.3B USD 100% through repurchases
Share count over 5 years
+2.1% more shares – dilution

What goes back to shareholders

Over 5 years, 5.3B USD went back to shareholders, 100% of it through share repurchases. That is 67% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 33.6M USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow −389.9M USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) 563.0M USD · Free cash flow −436.6M USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 0.0 USD · Free cash flow −490.5M USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 1.9B USD · Free cash flow 2.0B USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases 857.0M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 13.3B USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases 3.3B USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 4.6B USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 1.2B USD · New shares issued (including employee plans) not available · Free cash flow −3.8B USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow −4.1B USD
  10. Fiscal year 2025: Dividends paid not available · Share repurchases 2.0M USD · New shares issued (including employee plans) not available · Free cash flow −2.1B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Moderna next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison MRNA, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
MRNA Moderna this stock 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
NVAX Novavax 1.1B USD +18.8%93.5%40.3%39.2%–−10.9%−22.3%5/9
IOVA Iovance Biotherapeutics 263.5M USD –34.3%−153.1%−148.4%−56.0%76.5%−127.6%–
Median of the sector 26 symbols 44.4B USD +8.5%67.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector MRNA next to NVAX – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+19.3% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 19.3% per year on average – at least as fast as the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light red: Loss

−145.2% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue there was no profit but a loss of 145.16 USD. Five years ago the margin was −93.0%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.43 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.43 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light red: 8 loss years

2 of 10 fiscal years with a profit

What does this mean? In 2 of the last 10 fiscal years the bottom line showed a profit. 8 years ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
1.9B USD
Revenue vs. prior year
−39.9%
Net income (FY)
−2.8B USD
Net income vs. prior year
–
EPS (FY)
-7.26 USD
Superinvestors holding
2 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 20, 2026 · Balance sheet Sep 30, 2026 (filed Nov 6, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 1.9B−2.8B −145.2% −7.26 – –
2024Dec 31, 2024 3.2B−3.6B −110.0% −9.28 – –
2023Dec 31, 2023 6.8B−4.7B −68.8% −12.33 – –
2022Dec 31, 2022 19.3B8.4B 43.4% 20.12 – –
2021Dec 31, 2021 18.5B12.2B 66.1% 28.29 – –
2020Dec 31, 2020 803.4M−747.1M −93.0% −1.96 – –
2019Dec 31, 2019 60.2M−514.0M −853.7% −1.55 – –
2018Dec 31, 2018 135.1M−384.7M −284.8% – – –
2017Dec 31, 2017 205.8M−255.9M −124.3% – – –
2016Dec 31, 2016 108.4M−216.2M −199.5% – – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 1.3B162.0M 12.3% 0.38 – –
Q2/26Jun 30, 2026 145.0M−782.0M −539.3% −1.97 – –
Q1/26Mar 31, 2026 389.0M−1.3B −345.2% −3.40 – –
Q4/25*Dec 31, 2025 678.0M−826.0M −121.8% – – –
Q3/25Sep 30, 2025 1.0B−200.0M −19.7% −0.51 – –
Q2/25Jun 30, 2025 142.0M−825.0M −581.0% −2.13 – –
Q1/25Mar 31, 2025 108.0M−971.0M −899.1% −2.52 – –
Q4/24*Dec 31, 2024 966.0M−1.1B −115.9% – – –
Q3/24Sep 30, 2024 1.9B13.0M 0.7% 0.03 – –
Q2/24Jun 30, 2024 241.0M−1.3B −530.7% −3.33 – –
Q1/24Mar 31, 2024 167.0M−1.2B −703.6% −3.07 – –
Q4/23*Dec 31, 2023 2.8B217.0M 7.7% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $50.8M3 people −$50.8M
6 months $00 people $86.0M4 people −$86.0M
12 months $00 people $98.5M6 people −$98.5M

Latest transactions

  • Nov 17, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 157 shares · $33.6K · SEC
  • Nov 17, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 5,082 shares · $1.1M · SEC
  • Nov 17, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 33,976 shares · $7.2M · SEC
  • Nov 16, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 39,160 shares · $8.6M · SEC
  • Oct 15, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 39,145 shares · $8.6M · SEC
  • Oct 14, 2026 Hoge Stephen Officer Open-market sale · 10b5-1 plan 450 shares · $96.4K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Moderna?

All superinvestor portfolios

2 of 26 tracked superinvestors report a position.

Superinvestors with a position in Moderna, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Bridgewater Associates < 0.1% +527.6% increased Q3 2026
Steve Cohen Point72 Asset Management < 0.1% new Q3 2026

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score +30

Price vs. EMA 50-15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)-15
Highs and lows+10
Price change 60 days+15

Volatility and trend strength

ADX 14 (trend strength)pronounced (above 25)
Price change 60 daysup

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on MRNA yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MRNA

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close